Actinium Pharmaceuticals Announces Inducement Grant to New Employee

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM ) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced an inducement equity award to a newly hired non-executive employee. On October 26, 2026, the Company granted the employee a non-qualified stock option to purchase 3,000 shares of the Company's common stock at an exercise price of $1.40 per share, equal to the closing price of Actinium's common stock on the NYSE American on October 26, 2026. The option has a ten-year term; 28% of the shares underlying the option vest on the first anniversary of the grant date, and the remainder vest in equal monthly installments of 2% of the shares underlying the option over the following 36 months. Vesting of the award is subject to the employee's continued service with the Company through the applicable vesting date. The award was granted outside of the Company's Amended and Restated 2019 Stock Plan as an inducement material to the employee's entering into employment with the Company in accordance with Section 711(a) of the NYSE American Company Guide, and is subject to the terms of the Actinium Pharmaceuticals, Inc. 2026 Employment Inducement Award Plan and the applicable award agreement. About Actinium Pharmaceuticals, Inc. Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies. Its mission is to transform cancer treatment through innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining expertise in tumor biology, translational medicine, and radiochemistry. Since inception, Actinium has focused on developing innovative radiotherapies. Its pipeline reflects this strategy across three areas: (1) solid tumor therapeutics including ATNM-400 and Actimab-A with pan-tumor potential; (2) Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. ATNM-400 targets a novel antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer, and is being evaluated in a first-in-human Phase 1 study in mCRPC. Actimab-A has shown improved survival in relapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3 trial, with additional development ongoing through a CRADA with the NCI. Actinium is also advancing preclinical solid tumor programs and holds ~250 patents and patent applications, including intellectual property related to cyclotron-based production of Ac-225. For more information, please visit www.actiniumpharma.com . Forward-Looking Statements This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with the Company's ability to retain key personnel, the Company's ability to obtain additional financing on acceptable terms or at all, the conduct, timing and results of the Company's clinical trials, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time. Investors: [email protected] SOURCE Actinium Pharmaceuticals, Inc.